STJO yields 16666.67% · ABBV yields 3.06%● Live data
📍 STJO pulled ahead of the other in Year 1
Combined, STJO + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of STJO + ABBV for your $10,000?
St. Joseph, Inc., through its subsidiary, Staf*Tek Services, Inc., engages in the recruitment and placement of professional technical personnel, as well as finance and accounting personnel on a temporary and permanent basis primarily in the Tulsa, Oklahoma area. It provides its customers with employee candidates with information technology skills in areas ranging from multiple platform systems integration to end-user support, including specialists in programming, networking, systems integration, and database design, as well as help desk support comprising senior and entry level finance and accounting candidates. The company also offers computer training, online assessments, and certification in approximately 50 skill sets. It provides its services to a range of assignments from technical one-person assignments to major projects, such as Internet/Intranet development, desktop applications development, project management, enterprise systems development, SAP implementation, and mainframe projects. The company was formerly known as St. Joseph Energy, Inc. and changed its name to St. Joseph, Inc. in November 2003. St. Joseph, Inc. was founded in 1997 and is based in McKinney, Texas.
Full STJO Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.